NAUTILUS BIOTECHNOLOGY INC.
NAUTILUS BIOTECHNOLOGY INC.
- USD (-)
- 15 min delayed data - NASDAQ Stocks
Open: -
Change: -
Volume: -
Low: -
High: -
High / Low range: -
Type: Stocks
Ticker: NAUT
ISIN:

Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2021 Financial Results on February 24, 2022

  • 72

SEATTLE, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced it will report financial results for the fourth quarter and full year 2021 before market open on Thursday, February 24th, 2022.

The company’s management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the “Investors” section of the company website at: www.nautilus.bio.

About Nautilus Biotechnology, Inc.

Based in Seattle, Washington, Nautilus is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio

Contacts

Investors:
[email protected]

Media:
Thermal for Nautilus Biotechnology
Kaustuva Das
[email protected]

ti?nf=ODQ2NDI2MSM0Njk2NTc3IzIyMDgzMTI=
Nautilus-Biotechnology-Inc-.png

Primary Logo

GlobeNewsWire
GlobeNewsWire

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases, financial disclosures and multimedia content to media, investors, and consumers worldwide.